| __timestamp | Sarepta Therapeutics, Inc. | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 49315000 | 6795238 |
| Thursday, January 1, 2015 | 75043000 | 7454247 |
| Friday, January 1, 2016 | 83749000 | 10345862 |
| Sunday, January 1, 2017 | 122682000 | 16984203 |
| Monday, January 1, 2018 | 207761000 | 16187290 |
| Tuesday, January 1, 2019 | 284812000 | 9299233.54 |
| Wednesday, January 1, 2020 | 317875000 | 19232000 |
| Friday, January 1, 2021 | 282660000 | 23611000 |
| Saturday, January 1, 2022 | 451421000 | 26700000 |
| Sunday, January 1, 2023 | 481871000 | 28215000 |
Unleashing the power of data
In the competitive landscape of biotechnology, operational efficiency is key. Over the past decade, Summit Therapeutics Inc. and Sarepta Therapeutics, Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Sarepta's SG&A expenses surged by over 870%, reflecting its aggressive expansion and market penetration strategies. In contrast, Summit's expenses grew by approximately 315%, indicating a more conservative approach. Notably, in 2023, Sarepta's SG&A expenses were nearly 17 times higher than Summit's, highlighting the scale of its operations. This divergence underscores the varied strategic priorities of these companies, with Sarepta focusing on rapid growth and Summit maintaining a leaner operational model. As the biotech sector continues to evolve, these financial strategies will play a crucial role in shaping the future of these industry players.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Summit Therapeutics Inc.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Summit Therapeutics Inc.
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Summit Therapeutics Inc.
Neurocrine Biosciences, Inc. and Summit Therapeutics Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Merus N.V. Trends and Insights
Summit Therapeutics Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Insmed Incorporated vs Sarepta Therapeutics, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs TG Therapeutics, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Viridian Therapeutics, Inc. Trends and Insights